VMD Chief Medical Officer William Frazier Sells $117K of Stock
Chief Medical Officer William Frazier executed a sale of 10,000 shares of Viemed Healthcare, adding to a busy stretch of insider activity.
Reviewed by automated data checks against the source filing. How we make and check alerts
William Frazier, Chief Medical Officer at Viemed Healthcare, Inc. ($VMD), sold 10,000 shares at an average price of $11.72, worth about $117,200, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $VMD is up 2.8% after 1 week, up 3.7% after 1 month and down 18.9% to date (from the $11.69 close on Jun 25, 2026).
VMD
Viemed Healthcare, Inc.
Key Points
- Viemed Healthcare, Inc. Chief Medical Officer William Frazier sold 10,000 shares on June 25, 2026, at an average price of $11.72 per share for a total value of $117,200.
- The transaction followed a separate purchase of 10,000 shares by Frazier earlier on the same day at a price of $1.81 per share.
- Barrington Research recently initiated coverage on the stock with an Outperform rating and a $14.00 price target.
Get $VMD trade alerts by text
We text you when insiders, Congress or big funds trade $VMD. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Viemed Healthcare, Inc. alert may contain errors. Disclosures
William Frazier Executes Fresh Stock Transactions at Viemed Healthcare
Viemed Healthcare, Inc. (NasdaqCM: VMD) saw additional insider activity as Chief Medical Officer William Frazier parted with 10,000 shares on June 25, 2026. The transaction took place at a price of $11.72 per share, bringing the total value to $117,200. This sale came on the heels of other recent moves by company insiders, reflecting a pattern of active trading in the medical device firm's shares.
A Closer Look at the Recent Insider Activity
The June 25 sale by Frazier followed another transaction on the exact same day where he picked up 10,000 shares at a price of $1.81 per share, valued at $18,100. These trades continue a sequence of executive shifts in the stock. Just a day prior on June 24, Timothy Smokoff sold 20,000 shares at an average price of $11.50, totaling $229,968. Insider transactions like these offer a window into how individual executives manage their personal holdings over time.
Market Position and Recent Stock Performance
Viemed Healthcare shares trade around $11.63, resting comfortably between the 52-week low of $6.05 and the high of $12.61. The company carries a price-to-earnings ratio of 24.58 alongside a forward P/E of 22.13. With steady movement above key moving averages, market participants continue to watch how the equity responds to ongoing operational developments.
Recent Earnings and Financial Health
The medical equipment provider pulled in $301.6 million in revenue over the tracked period, paired with a revenue growth rate of 23.9%. Profitability metrics show a net margin of 4.81% and a return on equity of 10.45%. The firm reports a trailing earnings per share of $0.36. Shareholders await the next financial update when the company releases its upcoming earnings report on November 4, 2026.
Wall Street Analyst Coverage and Outlook
Analyst sentiment features a mix of recent views from major research houses. On August 24, Barrington Research initiated coverage on the stock with an Outperform rating and a target of $14.00. Earlier in the month on August 6, Freedom Broker adjusted its stance by issuing a Hold rating alongside an $11.00 price target. The consensus stance relies on a total of two analyst opinions carrying a mean target price of $12.50.
Understanding Viemed Healthcare
Viemed Healthcare operates out of Lafayette, Louisiana, supplying home medical equipment and post-acute respiratory healthcare services across the United States. The enterprise specializes in respiratory disease management solutions, including non-invasive ventilation, oxygen therapy, and sleep apnea treatment devices. These offerings support patients suffering from chronic conditions through dedicated in-home care solutions.
Looking Ahead for VMD Shares
Observers will monitor upcoming regulatory filings and Form 4 disclosures to track further insider adjustments. The next major milestone arrives with the scheduled earnings release on November 4, 2026, which will provide fresh insight into the firm's revenue trajectory and operational expenses.
Related Filing Alerts
Source: William Frazier's Form 4 filing on $VMD (Jun 25, 2026). Find the original filing: VMD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts